OBE001: an oxytocin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 52947354 |
| CHEMBL ID | 1254025 |
| SCHEMBL ID | 4424522 |
| SCHEMBL ID | 16550711 |
| MeSH ID | M000613618 |
| Synonym |
|---|
| (s)-(2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl)(2''-methylbiphenyl-4-yl)methanone |
| bdbm50326721 |
| CHEMBL1254025 , |
| nolasiban |
| erlosiban |
| SCHEMBL4424522 |
| nolasiban [who-dd] |
| obe001 |
| nolasiban [inn] |
| ((2s,4z)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl)(2'-methyl(1,1'-biphenyl)-4-yl)methanone |
| unii-3765u8a1ec |
| 3765u8a1ec , |
| 1477482-19-1 |
| erlosiban [inn] |
| 3-pyrrolidinone, 5-(hydroxymethyl)-1-((2'-methyl(1,1'-biphenyl)-4-yl)carbonyl)-, 3-(o-methyloxime), (3z,5s)- |
| SCHEMBL16550711 |
| OLUJSZLBWZWGJT-KOXKPCSVSA-N |
| (3e,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime |
| 3-pyrrolidinone,5-(hydroxymethyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-,3-(o-methyloxime),(5s)- |
| [(2s,4z)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone |
| [(2s,4z)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone |
OBE001 is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate.
| Excerpt | Reference | Relevance |
|---|---|---|
| "OBE001 is an orally active oxytocin receptor antagonist under development for preterm labour treatment." | ( Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. Chollet, A; Homery, MC; Lemaux, F; Patat, A; Pohl, O, 2015) | 1.42 |
| "OBE001 is a novel, orally active nonpeptide oxytocin receptor antagonist under development for the treatment of preterm labor and improvement in embryo implantation and pregnancy rate in assisted reproductive technology (ART). " | ( Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats. Baldrick, P; Chollet, A; Comotto, L; Perks, D; Pohl, O; Rhodes, J, 2016) | 2.12 |
Co-administration of OBE001 and betamethasone to determine pharmacokinetic interactions was studied during an open-label, randomized, three-period crossover study. There was no effect on geometric mean Cmax after the second administration. AUC and Cmax did not differ significantly between treatments.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Co-administration of OBE001 and betamethasone to determine pharmacokinetic interactions was studied during an open-label, randomized, three-period crossover study." | ( Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. Chollet, A; Homery, MC; Lemaux, F; Patat, A; Pohl, O, 2015) | 1.02 |
| "There was no effect on geometric mean Cmax after the second administration and AUCs of OBE001 [geometric mean ratio point estimate (90% CI): Cmax (Day2) 1·05 (0·98-1·12) and AUC(0-24 h )1·11 (0·99-1·23)/AUC(24 h-∞) 0·99 (0·93-1·06), respectively]; Cmax after the first administration together with betamethasone was increased by 12% [geometric mean ratio point estimates (90% CI): Cmax (Day1) 1·12 (0·96-1·32)]." | ( Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. Chollet, A; Homery, MC; Lemaux, F; Patat, A; Pohl, O, 2015) | 0.92 |
| "AUC and Cmax of the betamethasone and OBE001 combination did not differ significantly between treatments." | ( Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers. Chollet, A; Homery, MC; Lemaux, F; Patat, A; Pohl, O, 2015) | 0.97 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Oxytocin receptor | Homo sapiens (human) | Ki | 0.0950 | 0.0001 | 0.0718 | 0.9780 | AID513698 |
| Vasopressin V1a receptor | Homo sapiens (human) | Ki | 0.3300 | 0.0002 | 0.6235 | 7.0300 | AID513699 |
| Oxytocin receptor | Rattus norvegicus (Norway rat) | Ki | 0.2100 | 0.0009 | 0.0489 | 0.2300 | AID513702 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| peptide hormone binding | Oxytocin receptor | Homo sapiens (human) |
| peptide binding | Oxytocin receptor | Homo sapiens (human) |
| vasopressin receptor activity | Oxytocin receptor | Homo sapiens (human) |
| oxytocin receptor activity | Oxytocin receptor | Homo sapiens (human) |
| vasopressin receptor activity | Vasopressin V1a receptor | Homo sapiens (human) |
| protein kinase C binding | Vasopressin V1a receptor | Homo sapiens (human) |
| protein binding | Vasopressin V1a receptor | Homo sapiens (human) |
| peptide hormone binding | Vasopressin V1a receptor | Homo sapiens (human) |
| V1A vasopressin receptor binding | Vasopressin V1a receptor | Homo sapiens (human) |
| peptide binding | Vasopressin V1a receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Oxytocin receptor | Homo sapiens (human) |
| microvillus | Oxytocin receptor | Homo sapiens (human) |
| adherens junction | Oxytocin receptor | Homo sapiens (human) |
| apical plasma membrane | Oxytocin receptor | Homo sapiens (human) |
| plasma membrane | Oxytocin receptor | Homo sapiens (human) |
| endosome | Vasopressin V1a receptor | Homo sapiens (human) |
| plasma membrane | Vasopressin V1a receptor | Homo sapiens (human) |
| endocytic vesicle | Vasopressin V1a receptor | Homo sapiens (human) |
| plasma membrane | Vasopressin V1a receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID513698 | Displacement of [3H]-oxytocin from human oxytocin receptor expressed in CHO cells | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513699 | Displacement of [3H]vasopressin from human vasopressin V1a receptor expressed in CHO cells | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513690 | Oral bioavailability in rat | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513711 | Protein binding in human serum | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513702 | Displacement of [3H]-oxytocin from rat oxytocin receptor expressed in CHO cells | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513713 | Inhibition of oxytocin-induced uterine contraction in pregnant rat at 60 mg/kg, po | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513692 | Selectivity ratio of Ki for human oxytocin receptor Ki for human vasopressin V1a receptor | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513712 | Inhibition of oxytocin-induced uterine contraction in non-pregnant rat at 30 mg/kg, po | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| AID513708 | Inhibition of oxytocin-induced uterine contraction in po dosed rat | 2010 | Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18 | Oral oxytocin antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.81) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||